As clinical trials in the world grow and develop, so too do the opportunities for Spiral to make a difference with our savvy platform software. 

We speak to Professor Steven Tong about the SNAP Trial, his experience working with the team at Spiral, and the application and impact of our Spinnaker software in his study.

At Spiral, we’re always working hard to better meet the needs of our clients and partners. As our product evolves so too does our team. Meet Anna Williams, the newest full-time member of the Spiral whānau (family). Our office manager and data coordinator.  

The Bodleian Library is the main research library of the University of Oxford. It's one of the oldest libraries in Europe and is stacked with books dating back 600 years. Spiral’s CEO and Founder, Audrey Shearer found her recent visit here, while meeting clients for the Panoramic trial, a thought-provoking one.

Spinnaker Case Study—We speak with Dr Glenn Eastwood, TAME Chief Principal Investigator, about the TAME Trial study and how Spiral has enabled them to produce a database they can be confident in.

A new anti-viral, Paxlovid, has recently been added to the PANORAMIC national study in the UK. 

The efficacy of antiplatelet therapy in critically ill patients with COVID-19 has always been uncertain. However recent findings have shown that it’s unlikely that adding an antiplatelet agent to anticoagulation will increase the number of organ support-free days in critically ill patients with COVID-19. Although it’s possible that survival in the first 90 days can be improved, according to the results of the REMAP-CAP trial.

Meet Mel, the newest project manager to join our Spiral team. Mel has only been with us a few weeks but has settled into her role marvellously, bringing with her a background in project and account management as well as her recently acquired skills and knowledge in development.

Over ten thousand participants from right across the UK have now taken part in the NIHR-funded and supported PANORAMIC trial - the world’s largest study into new antiviral treatments against COVID-19 in community, ambulatory care.

REMAP-CAP, the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia, has recently hit a significant date in its trial history, celebrating two years since the first Covid-19 ICU patient was randomised into the trial.

The long-awaited results are finally here for the PLUS trial, an application in Spiral’s study manifest.

In a new development, we’re thrilled to report that the UK government has announced that thousands of the UK’s most vulnerable people will be among the first in the world to access these life-saving, cutting-edge antiviral and antibody treatments from December through the PANORAMIC trial.

Meet Adam. As the newest member to join our Spiral team, Adam has been with us for just over 6 months but has already brought with him a wealth of enthusiasm and keenness to take on a challenge.